FidoCure to Transform the Precision Medicine Landscape with New Patent, Accelerating Drug Development for Dogs with Cancer
The U.S. Patent and Trademark Office has granted FidoCure an industry-first patent for a novel targeted therapy and biomarker for canine cancer. The patent, assigned U.S. Patent No. 12036281-B2, is the first of its kind and covers a novel treatment approach guided by mutation profiling for managing bladder cancer in canine patients.
FidoCure's early data indicates that this therapy may be more efficacious than conventional treatments. The company will be seeking FDA approval for products, marking a significant step forward in veterinary oncology.
The patent not only protects FidoCure's technology for the next two decades but also sets a new standard in veterinary oncology. Co-founders Christina Lopes and Benjamin Lewis, and other key FidoCure team members, are listed as the inventors. Dr. Gerald Post, One Health Chief Medical Officer, emphasized the significance of this development, stating, "Bladder cancer in dogs is an unmet need as traditional chemotherapy and radiation therapy are often ineffective, cause toxic side effects, and are expensive."
With a pipeline of additional therapies in development, this patent grants FidoCure exclusive rights to commercialize this technology, supporting FidoCure's ongoing development of advanced veterinary oncology treatments in the multi-billion dollar pet cancer market. As FidoCure moves to first-in-class therapy drug development, it is ushering in a new era of accelerated drug development for beloved pets that leverages cutting-edge AI and data.
The FidoCure Approach
FidoCure's advanced AI technology analyzes the genomic data from canine tumors to identify the most effective biomarker and drug correlations, leveraging the world's largest structured canine cancer dataset. This vast repository contains over 2 billion data points collected from 1,350 veterinary clinics worldwide, enabling unprecedented insights into canine cancer treatment.
FidoCure's work is guided by an advisory team of globally distinguished leaders, including former FDA Deputy Commissioner Dr. Amy Abernethy and James Zou, director of Stanford's Data4Health hub. Their involvement further validates the potential of AI in developing personalized medicines and biomarker treatments derived from real-world evidence.
FidoCure CEO Christina Lopes stated, "This patent acknowledges the uniqueness of our approach, which has consistently demonstrated that it can transform outcomes for pet dogs with cancer while improving the quality of life for the patients." The company's pursuit of FDA approval for its products underscores its commitment to bringing innovative, effective treatments to the veterinary oncology field.